United States - English - NLM (National Library of Medicine)

med-pharmex, inc - dexpanthenol (unii: 1o6c93ri7z) (dexpanthenol - unii:1o6c93ri7z) - dexpanthenol 250 mg in 1 ml - composition: each ml contains: dexpanthenol………………………………..250 mg benzyl alcohol…………………………...…1% w/v water for injection……………….…………….. q.s. acetic acid, glacial, usp………….. to adjust ph indications: for use as a nutritional source of dexpanthenol. for animal use only keep out of reach of children take time observe label directions contraindications: in therapy of colic resulting from the administration of cholinergic type anthelmintics.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - vilanterol trifenatate, quantity: 40 microgram (equivalent: vilanterol, qty 25 microgram); fluticasone furoate, quantity: 100 microgram - inhalation, powder for - excipient ingredients: magnesium stearate; lactose monohydrate - copd,breo ellipta is indicated for symptomatic treatment of patients with copd with a fev1 <70% predicted normal (post-bronchodilator) in patients with an exacerbation history despite regular bronchodilator therapy.,breo ellipta is not indicated for the initiation of bronchodilator therapy in copd.,asthma,breo ellipta is indicated in the regular treatment of moderate to severe asthma in patients who require a medium to high dose inhaled corticosteroid combined with a long-acting beta-2-agonist.,vilanterol, an active ingredient in breo ellipta, is a long-acting beta-2-agonist (laba). a class effect of all labas can be an increased risk of asthma death (see precautions).

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - dexpanthenol - unknown - dexpanthenol ungrouped active 0.0 - active constituent

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone furoate, quantity: 200 microgram; vilanterol trifenatate, quantity: 40 microgram (equivalent: vilanterol, qty 25 microgram) - inhalation, powder for - excipient ingredients: magnesium stearate; lactose monohydrate - asthma,breo ellipta is indicated in the regular treatment of moderate to severe asthma in patients who require a medium to high dose inhaled corticosteroid combined with a long-acting beta-2-agonist.,vilanterol, an active ingredient in breo ellipta, is a long-acting beta-2-agonist (laba). a class effect of all labas can be an increased risk of asthma death (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - vilanterol trifenatate, quantity: 40 microgram (equivalent: vilanterol, qty 25 microgram); umeclidinium bromide, quantity: 74.2 microgram (equivalent: umeclidinium, qty 62.5 microgram); fluticasone furoate, quantity: 100 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate; magnesium stearate - asthma,trelegy ellipta is indicated for the maintenance treatment of asthma in adult patients who are not adequately controlled with a combination of inhaled corticosteroid and a long-acting beta2-agonist.,copd,trelegy ellipta is indicated for the maintenance treatment of adults with moderate to severe copd who require treatment with lama+laba+ics.,trelegy ellipta is not indicated for the initiation of therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - vilanterol trifenatate, quantity: 40 microgram (equivalent: vilanterol, qty 25 microgram); umeclidinium bromide, quantity: 74.2 microgram (equivalent: umeclidinium, qty 62.5 microgram); fluticasone furoate, quantity: 200 microgram - inhalation, powder for - excipient ingredients: lactose monohydrate; magnesium stearate - asthma,trelegy ellipta is indicated for the maintenance treatment of asthma in adult patients who are not adequately controlled with a combination of inhaled corticosteroid and a long-acting beta2-agonist.,copd,trelegy ellipta is indicated for the maintenance treatment of adults with moderate to severe copd who require treatment with lama+laba+ics.,trelegy ellipta is not indicated for the initiation of therapy in copd.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

nizhpharm jsc - dexpantenol, chlorhexidine (chlorhexidine digluconate) - cream for external use - 52,5mg/g+ 8,02mg/g

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

jurox pty limited - dexpanthenol - unknown - dexpanthenol ungrouped active 0.0 - active constituent

Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

awal pharmacy - d-panthenol - solution for external

Bahrain - English - الهيئة الوطنية لتنظيم المهن والخدمات الصحية، مملكة البحرين

awal pharmacy - d-panthenol - cream